ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma
Open Access
- 19 April 2019
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (6) , e22899
Abstract
Background: Estrogen‐related receptor gamma (ESRRG) has been identified as a tumor suppressor gene in several cancers. We aimed to evaluate ESRRG promoter methylation in laryngeal squamous cell carcinoma (LSCC) and its relative clinical value in LSCC.Methods: Bisulfite pyrosequencing assays were performed on 91 pairs of tumor and paracancer tissues from LSCC patients in China. The diagnostic value and overall survival (OS) were analyzed descriptively by receiver operating characteristic (ROC) curves and the Kaplan‐Meier methods, respectively.Results: The ESRRG promoter was more frequently hypermethylated in tumor tissues than in adjacent tissues (P < 0.01). ESRRG promoter methylation was significantly increased in advanced T stage tumors (P < 0.01) and advanced clinical stage patients (P < 0.01). Moreover, the area under the ROC curve (AUC) value (0.81) indicated high discrimination accuracy. Furthermore, ESRRG hypermethylation was associated with poor OS, as confirmed by Kaplan‐Meier survival curves (P < 0.01).Conclusion: Our study indicated that ESRRG promoter hypermethylation contributed to LSCC‐related risks, primarily tumor progression and survival prognosis, in patients. ESRRG promoter methylation could, therefore, be a diagnostic and prognostic biomarker in LSCC.Keywords
Funding Information
- Leading and Top Talents Training Projects of Ningbo (NBLJ201801032)
- Medical and Health Training Project of Zhejiang Province (2015RCB025)
- Ningbo Health Branding Subject Fund (PPXK2018-02)
- Zhejiang Provincial Natural Science Foundation of China (LY14H160003, No.LH19H160014)
- Scientific Innovation Team Project of Ningbo (2012B82019)
- Ningbo Social Developmental Key Research Project (2012C5015)
- Medical and Health Research Project of Zhejiang Province (2012ZDA042, 2014PYA017, 2018RC063, 2019ZD018)
This publication has 33 references indexed in Scilit:
- Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trialsCurrent Oncology, 2012
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: Comparison with methylation-specific PCR technique and clinical significanceMolecular Medicine Reports, 2011
- Nuclear receptor SHP inhibition of Dnmt1 expression via ERRγFEBS Letters, 2011
- Estrogen-Related Receptor Gamma Promotes Mesenchymal-to-Epithelial Transition and Suppresses Breast Tumor GrowthCancer Research, 2011
- Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosaOral Oncology, 2011
- Identification and Validation of DNA Methylation Markers to Predict Lymph Node Metastasis of Esophageal Squamous Cell CarcinomasAnnals of Surgical Oncology, 2010
- miR-378 ∗ Mediates Metabolic Shift in Breast Cancer Cells via the PGC-1β/ERRγ Transcriptional PathwayCell Metabolism, 2010
- Differential expression of estrogen‐related receptors β and γ (ERRβ and ERRγ) and their clinical significance in human prostate cancerCancer Science, 2010
- ERRγ Suppresses Cell Proliferation and Tumor Growth of Androgen-Sensitive and Androgen-Insensitive Prostate Cancer Cells and Its Implication as a Therapeutic Target for Prostate CancerCancer Research, 2007